AstraZeneca PLC - EMTN Programme Routine Technical Update
EMTN Programme Routine Technical Update: Publication of Prospectus
Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the Financial Conduct Authority and is available for viewing:
Base Prospectus for the
The last drawdown under the EMTN programme was in 2016.
To view the full document, please paste the following URL into the address bar of your browser.
A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in
This information is provided by RNS, the news service of the
Quick facts: AstraZeneca
Market Cap: £114.16 billion
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE